February 11th, 2020:
We are pleased to announce the publication of our article “A fully implantable device for diffuse insulin delivery at extraperitoneal site for physiological treatment of type 1 diabetes“. Magisson et al., Journal of Controlled Release (2020) 431-441; DOI 10.1016/j.jconrel.2020.01.055
Defymed is working on #ExOlin® since 2016 which should enter clinical trials in the upcoming months. In this article, we prove that diffuse administration of insulin at the extraperitoneal site via ExOlin® is superior to the commonly used SC-insulin administration on glucose control.
Read the paper and send us your question at email@example.com we will be very happy to answer.